Natera, Inc.
Natera, Inc. is a healthcare company specializing in genetic testing and diagnostics, with its most significant political signal being a $54,000 lobbying effort in 2021 focused on Medicaid coverage for prenatal screening and direct stock holdings by a former President.
BusinessWhat NTRA does
Natera, Inc. provides genetic testing and diagnostic services, primarily in oncology and women's health. Its revenue is derived from laboratory-developed tests, including non-invasive prenatal testing (NIPT) and circulating tumor DNA (ctDNA) testing for cancer detection and monitoring. The company operates in a highly regulated reimbursement environment dependent on public and private payer coverage.
Executive Branch ConflictsNTRA held by Trump-administration officials
Lifetime Government AwardsNTRA federal contracts
NTRA doesn't hold direct federal contracts.
Verified via USASpending.gov: $0 reported in direct prime-contract awards. Companies in this position typically sell federal services indirectly through prime contractors and integrators (e.g., Lockheed Martin, Booz Allen, Microsoft Azure) or through commercial channels that don't appear in USASpending data.
Politicians Trading NTRAMembers of Congress with recent NTRA positions
Congressional TradesWho in Congress is trading NTRA
Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock
No Form 4 activity recorded in the last 180 days.
Bills Affecting NTRALive legislation impacting this stock
Political ProfileWhere NTRA sits in Washington
[object Object]
STRUCTURAL: Lobbying alignment with 3 committee members (Gottheimer, Goldman, Hagerty) on a specific bill for Medicaid coverage expansion ($54,000 spend). EVIDENTIARY: Direct stock holdings by a former President (Donald J. Trump, value $15,001-$50,000 per `get_executive_branch_exposure.by_ticker[0].holdings[1]`) and active congressional trading (Rep. Gottheimer, 6 trades in 12 months per `Top congressional traders`). Net: Strong structural targeting of reimbursement policy combined with high-level ownership and trading activity.
Regulatory ExposureThreats & opportunities
Regulatory threats
-
Medicaid reimbursement policy changes for genetic screening tests.Centers for Medicare & Medicaid Services (CMS)"Lobbying filings specifically target H.R. 1439 to amend Medicaid coverage for prenatal screening (`Lobbying filings touching this ticker[0].specific_issues`)."
Regulatory opportunities
-
Expanded federal coverage mandates for non-invasive prenatal genetic screening.Centers for Medicare & Medicaid Services (CMS)"Lobbying efforts in 2021 were exclusively focused on H.R. 1439 to provide Medicaid coverage for NIPT (`Lobbying filings touching this ticker`)."
Capitol Hill AlliesChampions & critics
Congressional champions
Congressional critics
- No specific congressional critics identified.
LobbyingWho's hired to advocate for NTRA
Live signals + predictions for NTRA — for Founders
The free page above gives you the public record. Members see the real-time intelligence layer on top of it:
- Live 7-layer signal scores when Congress trades NTRA
- Bill Pass Index v2 odds for every bill on the watch list
- Iron Triangle alerts (committee × donor × trade)
- SEC Form 4 cluster detection (CEO + CFO + director buys)
- Whale-Opportunity expected-value ranking
- Custom watchlist alerts via email + Discord